Subsequently, we performed a subcategory analysis according to different cutoff values of ALDH1A1 expression (>5% and >0%/1% subgroups), different regions the patients originated from (America-Europe, Asia, and Africa subgroups), different clinical stages of the patients [No assesment (NA) and ≥ stage II subgroups], different antibodies used in the studies (BD subgroup and Abcam subgroup), and types of surgery for patients [Surgery, Part surgery, and No screened (NS) subgroups]. This evidence concerns the gene ALDH1A1 and Behcet disease.